[go: up one dir, main page]

MX2012000316A - Anticuerpos humanizados para el receptor 2 tipo toll y usos de los mismos. - Google Patents

Anticuerpos humanizados para el receptor 2 tipo toll y usos de los mismos.

Info

Publication number
MX2012000316A
MX2012000316A MX2012000316A MX2012000316A MX2012000316A MX 2012000316 A MX2012000316 A MX 2012000316A MX 2012000316 A MX2012000316 A MX 2012000316A MX 2012000316 A MX2012000316 A MX 2012000316A MX 2012000316 A MX2012000316 A MX 2012000316A
Authority
MX
Mexico
Prior art keywords
toll
receptor
amino acid
acid sequence
sequence
Prior art date
Application number
MX2012000316A
Other languages
English (en)
Inventor
Jerome Dellacasagrande
Original Assignee
Opsona Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opsona Therapeutics Ltd filed Critical Opsona Therapeutics Ltd
Publication of MX2012000316A publication Critical patent/MX2012000316A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Abstract

Un anticuerpo completamente humanizado que tiene especificidad de unión al Receptor 2 tipo Toll comprende una cadena ligera y una cadena pesada completamente comprenda de la secuencia de aminoácidos de origen humano. La región variable de la cadena ligera comprende una secuencia de aminoácidos que es sustancialmente homóloga con la secuencia de SEQ ID NO:1, en donde la región variable del dominio pesado comprende una secuencia de aminoácidos que es sustancialmente homóloga con la secuencia de SEQ ID NO:4. También se proporcionan ácidos nucleicos que codifican para estos anticuerpos, así como el uso de los anticuerpos en medicina, en particular para el tratamiento de enfermedades inflamatorias y autoinmunitarias que se medían por la señalización y activación del Receptor 2 tipo Toll.
MX2012000316A 2009-07-06 2010-07-06 Anticuerpos humanizados para el receptor 2 tipo toll y usos de los mismos. MX2012000316A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27023909P 2009-07-06 2009-07-06
IE20090514A IE20090514A1 (en) 2009-07-06 2009-07-06 Humanised antibodies and uses therof
PCT/EP2010/059677 WO2011003925A1 (en) 2009-07-06 2010-07-06 Humanised antibodies to toll-like receptor 2 and uses thereof

Publications (1)

Publication Number Publication Date
MX2012000316A true MX2012000316A (es) 2012-04-20

Family

ID=43428820

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012000316A MX2012000316A (es) 2009-07-06 2010-07-06 Anticuerpos humanizados para el receptor 2 tipo toll y usos de los mismos.

Country Status (16)

Country Link
US (1) US8734794B2 (es)
EP (2) EP2805973B1 (es)
JP (2) JP5847707B2 (es)
KR (1) KR101572171B1 (es)
CN (1) CN102482356B (es)
AU (1) AU2010270241B2 (es)
BR (1) BRPI1014016B8 (es)
CA (1) CA2766996C (es)
ES (2) ES2658224T3 (es)
IE (1) IE20090514A1 (es)
IL (1) IL217225A (es)
IN (1) IN2012DN00938A (es)
MX (1) MX2012000316A (es)
NZ (2) NZ615441A (es)
RU (1) RU2563344C2 (es)
WO (1) WO2011003925A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201205633D0 (en) 2012-03-30 2012-05-16 Opsona Therapeutics Ltd Toll-like receptor 2 binding epitope and binding members thereto
EP2722342A1 (en) 2012-10-19 2014-04-23 Opsona Therapeutics Limited Methods and compositions for the treatment of pancreatic cancer
US10047164B2 (en) 2012-10-19 2018-08-14 Opsona Therapeutics Limited Methods and compositions for the treatment of pancreatic cancer
KR101478426B1 (ko) 2013-02-08 2014-12-31 아주대학교산학협력단 톨 유사 수용체 2를 포함하는 백질 뇌졸중 검출용 바이오마커 및 톨 유사 수용체 2의 의학적 용도
JP6366195B2 (ja) * 2013-04-22 2018-08-01 国立大学法人 東京大学 炎症性疾患の予防又は治療剤
CN103319600B (zh) * 2013-06-19 2014-12-17 南京军区军事医学研究所 一种人源抗TLR4抗体Fab及其制备方法与应用
EP3112462B1 (en) * 2014-02-28 2018-12-05 Astellas Pharma Inc. Novel bispecific antibody binding to human tlr2 and human tlr4
CN104403001B (zh) * 2014-12-12 2018-01-16 中国人民解放军南京军区军事医学研究所 一种全人源抗TLR4的抗体Fab及其全分子抗体IgG和应用
TWI703156B (zh) * 2015-01-30 2020-09-01 學校法人埼玉醫科大學 抗ａｌｋ２抗體
FR3048971A1 (fr) * 2016-03-15 2017-09-22 Univ Rabelais Francois Constructions peptidiques bispecifiques et leur utilisation dans le traitement de maladies notamment imflammatoires
WO2018099614A1 (en) 2016-12-02 2018-06-07 Opsona Therapeutics Limited Methods and compositions for the treatment of myelodysplastic syndrome
AU2017381598B2 (en) * 2016-12-22 2023-12-21 Avectas Limited Vector-free intracellular delivery by reversible permeabilisation
US11634495B2 (en) 2017-04-07 2023-04-25 Miltenyi Biotec B.V. & Co. KG Methods of activating CD32b/c comprising administering an antibody that binds BDCA-2 (CD303)
EP3746478A4 (en) * 2018-01-29 2022-01-19 The Regents of The University of California THERAPIES AND METHODS OF TREATING TLR2-MEDIATED DISEASES AND DISORDERS
EP3583949A1 (en) 2018-06-19 2019-12-25 Opsona Therapeutics Limited Toll-like receptor 2 (tlr2) antagonists for the treatment of ovarian cancer
KR20200050715A (ko) * 2018-11-02 2020-05-12 주식회사 젠센 Tlr 억제 펩타이드를 포함하는 루푸스 예방 또는 치료용 조성물
CN111109198B (zh) * 2019-03-29 2021-08-20 成都华西海圻医药科技有限公司 一种葡萄膜炎动物模型构建方法
CN111393530A (zh) * 2020-03-30 2020-07-10 中国人民解放军南部战区总医院 新人源tlr2胞外区段单克隆抗体及其制备方法和应用
WO2023154799A1 (en) 2022-02-14 2023-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination immunotherapy for treating cancer
WO2024194686A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
KR102790119B1 (ko) * 2023-05-09 2025-04-08 주식회사 뉴라메디 항 tlr2 항체 및 이의 용도

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
CA2110799A1 (en) 1991-06-14 1992-12-23 Arnold H. Horwitz Microbially-produced antibody fragments and their conjugates
US5885793A (en) 1991-12-02 1999-03-23 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9927332D0 (en) * 1999-11-18 2000-01-12 Leiv Eiriksson Nyfotek As Novel antibody and uses thereof
ATE448301T1 (de) 2000-09-08 2009-11-15 Univ Zuerich Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
US20050089932A1 (en) 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
ZA200510028B (en) * 2003-06-20 2007-03-28 Coley Pharm Gmbh Small molicule toll-like receptor (TLR) antagonists
WO2005019431A2 (en) 2003-08-20 2005-03-03 University Of Massachusetts Selective inhibition of toll-like receptor-2
ATE510853T1 (de) * 2003-09-23 2011-06-15 Univ Muenchen Tech Tlr2-antagonistischer antikörper und dessen verwendung
US20050164301A1 (en) 2003-10-24 2005-07-28 Avidia Research Institute LDL receptor class A and EGF domain monomers and multimers
CN101415438B (zh) * 2004-11-30 2013-03-27 森托科尔公司 Toll样受体3拮抗剂、方法和用途
WO2006082406A2 (en) 2005-02-03 2006-08-10 Antitope Limited Human antibodies and proteins
EP1929073A4 (en) 2005-09-27 2010-03-10 Amunix Inc PROTEIN MEDICAMENT AND ITS USE
PL1989544T3 (pl) 2006-03-02 2012-01-31 Antitope Ltd Testy na komórkach T
US8546539B2 (en) * 2007-05-14 2013-10-01 Novimmune S.A. Fc receptor-binding polypeptides with modified effector functions
EP2170366B1 (en) * 2007-08-03 2013-11-06 Opsona Therapeutics Limited Use of tlr-2 antagonists for treatment of reperfusion injury and tissue damage

Also Published As

Publication number Publication date
IL217225A (en) 2017-08-31
RU2563344C2 (ru) 2015-09-20
KR20120075457A (ko) 2012-07-06
JP5847707B2 (ja) 2016-01-27
RU2011153932A (ru) 2013-08-20
CN102482356A (zh) 2012-05-30
CA2766996C (en) 2017-08-01
IE20090514A1 (en) 2011-02-16
JP2012531922A (ja) 2012-12-13
CN102482356B (zh) 2016-05-25
BRPI1014016A2 (pt) 2016-09-13
WO2011003925A1 (en) 2011-01-13
BRPI1014016B1 (pt) 2020-04-07
US8734794B2 (en) 2014-05-27
IN2012DN00938A (es) 2015-04-03
CA2766996A1 (en) 2011-01-13
EP2451842B1 (en) 2014-05-14
AU2010270241B2 (en) 2015-02-19
EP2451842A1 (en) 2012-05-16
ES2658224T3 (es) 2018-03-08
BRPI1014016B8 (pt) 2020-05-19
ES2488615T3 (es) 2014-08-28
AU2010270241A1 (en) 2012-02-02
EP2805973B1 (en) 2017-11-08
JP6677466B2 (ja) 2020-04-08
EP2805973A2 (en) 2014-11-26
KR101572171B1 (ko) 2015-11-26
JP2016025863A (ja) 2016-02-12
EP2805973A3 (en) 2015-03-04
IL217225A0 (en) 2012-02-29
US20120164159A1 (en) 2012-06-28
NZ597447A (en) 2013-12-20
NZ615441A (en) 2014-10-31

Similar Documents

Publication Publication Date Title
MX2012000316A (es) Anticuerpos humanizados para el receptor 2 tipo toll y usos de los mismos.
NZ601271A (en) Cd127 binding proteins
NZ599140A (en) Antibodies that specifically bind to the epha2 receptor
MY183134A (en) Anti-cemx antibodies capable of binding to human mlge on b lymphocytes
EA201400568A1 (ru) Альбуминсвязывающие антитела и их связывающие фрагменты
NZ595792A (en) Antibodies specific to cadherin-17
NZ607969A (en) Cd33 binding agents
MX2010009190A (es) Anticuerpos anti-c5ar humanizados.
PH12014500167A1 (en) Tnf-alpha antigen-binding proteins with increased fcrn binding
NZ603499A (en) Human cytomegalovirus neutralizing antibodies and uses thereof
NZ703653A (en) Anti-fap antibodies and methods of use
NZ610091A (en) Antibodies
NZ612512A (en) Use of chimeric antigen receptor-modified t cells to treat cancer
WO2010017103A3 (en) Fully human anti-human nkg2d monoclonal antibodies
NZ602892A (en) Antibodies that bind human cd27 and uses thereof
PE20191408A1 (es) Proteinas de union a antigeno st2
MX2012011405A (es) Anticuerpo biespecifico psmaxcd3 de simple cadena especifico de especies cruzadas.
NZ589436A (en) Dual variable domain immunoglobulins and uses thereof
TN2011000528A1 (en) Compositions and methods for antibodies targeting complement protein c3b
NZ599193A (en) Siglec 15 antibodies in treating bone loss-related disease
UA106607C2 (uk) Білки специфічного зв'язування і їх застосування
EA201490677A1 (ru) Связывающие антиген cd27l белки
MX361929B (es) Anticuerpos anti-ligando de quimiocina cc 20 (ccl20) neutralizantes.
NZ594682A (en) Fully human antibodies specific to cadm1
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof

Legal Events

Date Code Title Description
FG Grant or registration